Based on the Ultrasound Evaluating the Effect of Xiaozhong Fang Particles for Knee Osteoarthritic With Synovial Fluid

Sponsor
Beijing University of Chinese Medicine (Other)
Overall Status
Unknown status
CT.gov ID
NCT03586700
Collaborator
(none)
50
1
2
37.5
1.3

Study Details

Study Description

Brief Summary

This study is a randomized, single blind, controlled trial. Aim to compare the effectiveness (especially the absorption degree of the synovial effusion measured by B ultrasonic) of the treatment group with the control group. The treatment group was given Xiao zhong fang granules orally and short wave infrared radiation and the control group was given the placebo Xiao zhong fang granules orally and short wave infrared radiation. To evaluate the clinical efficacy of the Chinese medicine in the treatment of the synovial effusion of knee osteoarthritis.

Condition or Disease Intervention/Treatment Phase
  • Drug: Xiao zhong fang granules
  • Radiation: Short wave infrared radiation
  • Drug: Placebo Xiao zhong fang granules
Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Based on the Ultrasound Evaluating the Effect of Xiaozhong Fang Particles for Knee Osteoarthritic With Synovial Fluid
Actual Study Start Date :
Sep 15, 2017
Anticipated Primary Completion Date :
Aug 31, 2020
Anticipated Study Completion Date :
Oct 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Xiao zhong fang granules

Xiao zhong fang granules were made from Smilax glabra 20g, Paris polyphylla 10g, Alisma orientale15g, Plantago15g, Peach kernel 10g, safflower 10g, radices cyathulae10g,fructus chaenomeles lagenaria 10g, corydalis tuber 10g, radix clematis 10g, radices paeoniae alba 10g, glycyrrhiza 10g. Granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.

Drug: Xiao zhong fang granules
Chinese medicine Xiao zhong fang was Professor Sun Chengxiang's experience formula in Massage Department of Dongzhimen Hospital. The function of the formula is to activate blood circulation and dredge collaterals, tonifying kidney and promoting dampness to soothe the liver and nourish tendons.

Radiation: Short wave infrared radiation
Short waves infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.

Placebo Comparator: Placebo Xiao zhong fang granules

Placebo Xiao zhong fang granules were made by the same institution. Placebo granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.

Radiation: Short wave infrared radiation
Short waves infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.

Drug: Placebo Xiao zhong fang granules
Made of starch,dextrin and edible pigment from Dongzhimen Hospital of Beijing university of chinese medicine.

Outcome Measures

Primary Outcome Measures

  1. Walther grading of synovial effusion of Knee joint [After treatment(28days)]

    The Walther grading standard of the synovial effusion of the knee joint (measuring the anterior and posterior diameter of the effusion): the 0 level is the joint cavity without effusion or the expansion of joint capsule<2mm; the grade I is a small amount of effusion, the expansion of joint capsule is 2mm-5mm; the grade II is a medium amount of effusion, the expansion of joint capsule is 6mm-10mm; the grade III is a large amount of effusion, and the joint capsule expands >10mm.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
    1. the American Society of Rheumatology established the diagnostic criteria for knee OA in 2001;
    1. Kellgren/Lawrence score of knee joint grade as I,II and early III.
    1. According to "Principles of clinical guidance for new drugs of traditional Chinese Medicine ",diagnosed as "Xi Bi Disease".
    1. Patients with informed consent.
  • 5)Blood and urine routine tests, liver and kidney functions, electrocardiogram were normal before recruitment.

    1. Patients were not treated with NSAIDS drugs or hormone drugs, and no patients were treated with drugs related to this disease at least 2 weeks.
Exclusion Criteria:
  • 1)Patients suffer from other rheumatic and metabolic diseases such as gout, rheumatoid arthritis, diabetes and so on.

    1. Patients with knee joint inflammatory infection, such as suppurative and nonspecific.
  • 3)Patients accompanied by traumatic synovitis, Villonodular pigmented synovitis, synovial membrane of the knee is the main lesion.

    1. Patients with informed consent.
  • 5)The color of joint fluid of patients' knees is pink or other color or cloudy; the white blood cell counts > 1000 /mm3 or with crystal in the joint fluid.

  • 6)Patients blood RF > 30IU/ml, ESR > 20mm/h, CRP > 10mg/L.

  • 7)Patients combined with severe cardiovascular, cerebrovascular, liver, kidney and other primary diseases and mental diseases.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dongzhimen Hospital Beijing University of Chinese Medicine Beijing Bejiing China 100700

Sponsors and Collaborators

  • Beijing University of Chinese Medicine

Investigators

  • Principal Investigator: DUODUO LI, MASTER, Dongzhimen Hospital, Beijing University of Chinese Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
mei han, Assistant Researcher, Beijing University of Chinese Medicine
ClinicalTrials.gov Identifier:
NCT03586700
Other Study ID Numbers:
  • QN2016-03
First Posted:
Jul 16, 2018
Last Update Posted:
Jul 16, 2018
Last Verified:
Jul 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by mei han, Assistant Researcher, Beijing University of Chinese Medicine
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 16, 2018